GDC 0980

Known as: Dual PI3 Kinase/mTOR Inhibitor GDC-0980, GDC-0980, GDC0980 
An orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling… (More)

Topic mentions per year

Topic mentions per year

2010-2018
0246820102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
BACKGROUND The current single-arm, open-label trial was designed to evaluate the activity of apitolisib (GDC-0980), a dual… (More)
Is this relevant?
2016
2016
PURPOSE This first-in-human phase I trial assessed the safety, tolerability, and preliminary antitumor activity of apitolisib… (More)
Is this relevant?
2016
2016
PURPOSE To the best of our knowledge, this study is the first to compare dual inhibition of PI3K/mammalian target of rapamycin… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2014
2014
Pancreatic cancer remains fatal to the fast majority of affected patients. Activation of phosphoinositide-3 kinase (PI3K)-AKT… (More)
Is this relevant?
2014
2014
Triple negative breast cancer (TNBC) is a heterogeneous collection of biologically diverse cancers, which contributes to variable… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
OBJECTIVE To evaluate PIK3CA mutational status and c-erbB2 gene amplification in a series of primary uterine serous carcinomas… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
(S)-1-{4-[2-(2-Amino-pyrimidin-5-yl)-7-methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl]-piperazin-1-yl}-2-hydroxy… (More)
  • figure 1
  • table 2
  • table 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Alterations of the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway occur broadly in cancer via multiple mechanisms… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
The discovery of 2 (GDC-0980), a class I PI3K and mTOR kinase inhibitor for oncology indications, is described. mTOR inhibition… (More)
Is this relevant?
2011
2011
3020 Background: The PI3K-AKT-mTOR signaling pathway is deregulated in a wide variety of cancers. GDC-0980 is a potent, selective… (More)
Is this relevant?